34874603|t|Normal cerebrospinal fluid concentrations of PDGFRbeta in patients with cerebral amyloid angiopathy and Alzheimer's disease.
34874603|a|BACKGROUND: Cerebrospinal fluid (CSF) platelet-derived growth factor receptor-beta (PDGFRbeta) has been proposed as a biomarker of blood-brain barrier (BBB) breakdown. We studied PDGFRbeta levels as a biomarker for cerebral amyloid angiopathy (CAA), amnestic mild cognitive impairment (aMCI), or Alzheimer's disease (AD). METHODS: CSF PDGFRbeta levels were quantified by enzyme-linked immunosorbent assay in patients with CAA, patients with aMCI/AD, and in matched controls. In aMCI/AD we evaluated CSF PDGFRbeta both by clinical phenotype and by using the AT(N) biomarker classification system defined by CSF amyloid (A), tau (T), and neurodegeneration (N) biomarkers. RESULTS: PDGFRbeta levels were similar in CAA patients and controls (P = .78) and in aMCI/AD clinical phenotype and controls (P = .91). aMCI/AD patients with an AD+ biomarker profile (A+T+[N+]) had increased PDGFRbeta levels compared to (A-T-[N-]) controls (P = .006). CONCLUSION: Our findings indicate that PDGFRbeta levels are associated with an AD+ biomarker profile but are not a suitable biomarker for CAA or aMCI/AD clinical syndrome.
34874603	45	54	PDGFRbeta	Gene	5159
34874603	58	66	patients	Species	9606
34874603	72	99	cerebral amyloid angiopathy	Disease	MESH:D016657
34874603	104	123	Alzheimer's disease	Disease	MESH:D000544
34874603	163	207	platelet-derived growth factor receptor-beta	Gene	5159
34874603	209	218	PDGFRbeta	Gene	5159
34874603	304	313	PDGFRbeta	Gene	5159
34874603	340	367	cerebral amyloid angiopathy	Disease	MESH:D016657
34874603	369	372	CAA	Disease	MESH:D016657
34874603	375	409	amnestic mild cognitive impairment	Disease	MESH:D060825
34874603	411	415	aMCI	Disease	MESH:D060825
34874603	421	440	Alzheimer's disease	Disease	MESH:D000544
34874603	442	444	AD	Disease	MESH:D000544
34874603	460	469	PDGFRbeta	Gene	5159
34874603	533	541	patients	Species	9606
34874603	547	550	CAA	Disease	MESH:D016657
34874603	552	560	patients	Species	9606
34874603	566	570	aMCI	Disease	MESH:D060825
34874603	571	573	AD	Disease	MESH:D000544
34874603	603	607	aMCI	Disease	MESH:D060825
34874603	608	610	AD	Disease	MESH:D000544
34874603	628	637	PDGFRbeta	Gene	5159
34874603	735	742	amyloid	Disease	MESH:C000718787
34874603	748	751	tau	Gene	4137
34874603	761	778	neurodegeneration	Disease	MESH:D019636
34874603	804	813	PDGFRbeta	Gene	5159
34874603	837	840	CAA	Disease	MESH:D016657
34874603	841	849	patients	Species	9606
34874603	880	884	aMCI	Disease	MESH:D060825
34874603	885	887	AD	Disease	MESH:D000544
34874603	931	935	aMCI	Disease	MESH:D060825
34874603	936	938	AD	Disease	MESH:D000544
34874603	939	947	patients	Species	9606
34874603	956	958	AD	Disease	MESH:D000544
34874603	1003	1012	PDGFRbeta	Gene	5159
34874603	1103	1112	PDGFRbeta	Gene	5159
34874603	1143	1145	AD	Disease	MESH:D000544
34874603	1202	1205	CAA	Disease	MESH:D016657
34874603	1209	1213	aMCI	Disease	MESH:D060825
34874603	1214	1234	AD clinical syndrome	Disease	MESH:D000544
34874603	Association	MESH:D000544	5159

